U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07356960) titled 'Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world' on Jan. 12.
Brief Summary: The goal of this retrospective observational study is to learn about the efficacy of ponatinib in Philadelphia-positive ALL (Ph+ ALL) patients in a real-world setting. The main goal of the study is to assess the rate of complete molecular response (CMR) induced by ponatinib in patients treated under the regulations of Law 648/96, outside clinical trials.
Patients who were treated with ponatinib as part of their regular medical care and completed the follow-up period will be included in the study.
Study Start Date: April 02, 2026
Study...